Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in sepsis-associated lymphopenia
2018-003977-93Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Mar 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis comparing CYT107 with Placebo (2 arms). Primary endpoint: Increase in absolute lymphocyte count at day 29. Started Mar 2019; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
sepsis
Beyond the preview
Go deeper on 2018-003977-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003977-93.